Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    BiondVax Pharmaceuticals Ltd. (BVXV)

    Price:

    1.36 USD

    ( + 0.01 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    BVXV
    Name
    BiondVax Pharmaceuticals Ltd.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.360
    Market Cap
    4.967M
    Enterprise value
    34.365M
    Currency
    USD
    Ceo
    Amir Reichman
    Full Time Employees
    33
    Ipo Date
    2015-05-12
    City
    Jerusalem
    Address
    Jerusalem BioPark Building

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    61.406B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    99.056B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.254B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -22.366
    P/S
    0
    P/B
    -6.748
    Debt/Equity
    -12.240
    EV/FCF
    -2.988
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.045
    Debt/assets
    0.796
    FUNDAMENTALS
    Net debt/ebidta
    -0.711
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.115
    Capex to revenue
    0
    Capex to depreciation
    1.488
    Return on tangible assets
    -0.020
    Debt to market cap
    1.287
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    -0.066
    P/CF
    -1.634
    P/FCF
    -2.066
    RoA %
    -1.962
    RoIC %
    -4.035
    Gross Profit Margin %
    0
    Quick Ratio
    6.146
    Current Ratio
    6.146
    Net Profit Margin %
    0
    Net-Net
    -5.662
    FUNDAMENTALS PER SHARE
    FCF per share
    -3.127
    Revenue per share
    0
    Net income per share
    -0.205
    Operating cash flow per share
    -2.804
    Free cash flow per share
    -3.127
    Cash per share
    5.432
    Book value per share
    -0.679
    Tangible book value per share
    -0.679
    Shareholders equity per share
    -0.679
    Interest debt per share
    8.314
    TECHNICAL
    52 weeks high
    11.490
    52 weeks low
    0.630
    Current trading session High
    1.360
    Current trading session Low
    1.310
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.478
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -5.3900312999999995%
    P/E
    -0.087
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.928
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.773
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.124
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -87.894
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.708
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -3.2224856%
    P/E
    -0.674

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.474
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -5345.3063999999995%
    P/E
    -0.301
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.605
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.107
    logo

    Country
    CH
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.820
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.061

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.697
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.446
    logo

    Country
    NL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.408
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.348
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.990
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.550
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.161
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.877
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.113
    DESCRIPTION

    BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

    NEWS
    https://images.financialmodelingprep.com/news/biondvax-pharmaceuticals-ltd-rebrands-as-scinai-immunotherapeutics-ltd-20230906.jpg
    BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd.

    globenewswire.com

    2023-09-06 06:00:00

    Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI”

    https://images.financialmodelingprep.com/news/biondvax-reports-second-quarter-financial-results-and-provides-business-20230811.jpg
    BiondVax Reports Second Quarter Financial Results and Provides Business Update

    globenewswire.com

    2023-08-11 09:00:00

    JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.

    https://images.financialmodelingprep.com/news/nasdaq-grants-biondvax-extension-to-regain-compliance-with-listing-rules-20230801.jpg
    Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

    globenewswire.com

    2023-08-01 16:01:00

    JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-bioeurope-spring-20230316.jpg
    BiondVax to Present at BIO-Europe Spring

    globenewswire.com

    2023-03-16 13:10:00

    JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.

    https://images.financialmodelingprep.com/news/biondvax-presenting-at-bio-ceo-investor-conference-20230202.jpg
    BiondVax Presenting at BIO CEO & Investor Conference

    globenewswire.com

    2023-02-02 14:15:00

    JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.

    https://images.financialmodelingprep.com/news/best-penny-stocks-to-buy-5-to-watch-after-20230123.jpg
    Best Penny Stocks To Buy? 5 To Watch After Big News This Week

    pennystocks.com

    2023-01-23 09:28:30

    Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

    https://images.financialmodelingprep.com/news/biondvax-ceo-to-present-at-the-january-2023-biotech-20221121.jpg
    BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco

    prnewswire.com

    2022-11-21 06:00:00

    JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-recent-advances-in-fermentation-technology-20221103.jpg
    BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

    prnewswire.com

    2022-11-03 11:30:00

    JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-ld-micro-investor-conference-in-20221018.jpg
    BiondVax to Present at LD Micro Investor Conference in Los Angeles

    newsfilecorp.com

    2022-10-18 07:55:00

    Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-ld-micro-investor-conference-in-20221011.jpg
    BiondVax to present at LD Micro Investor Conference in Los Angeles

    prnewswire.com

    2022-10-11 14:00:00

    JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-hc-wainwright-24th-annual-global-investment-20220908.jpg
    BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference

    prnewswire.com

    2022-09-08 09:13:00

    JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

    https://images.financialmodelingprep.com/news/biondvax-to-present-at-this-weeks-biomed-israel-conference-20220509.jpg
    BiondVax to Present at this week's Biomed Israel Conference

    prnewswire.com

    2022-05-09 06:00:00

    JERUSALEM  , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.

    https://images.financialmodelingprep.com/news/biondvax-pharmaceuticals-ltd-bvxv-ceo-amir-reichman-on-q4-2021-20220404.jpg
    BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

    seekingalpha.com

    2022-04-04 15:23:08

    BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

    https://images.financialmodelingprep.com/news/biondvax-announces-fourth-quarter-and-full-year-2021-financial-20220328.jpg
    BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

    prnewswire.com

    2022-03-28 07:00:00

    JERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2021 and provided a business update.

    https://images.financialmodelingprep.com/news/why-is-biondvax-bvxv-stock-up-today-20220324.jpg
    Why Is BiondVax (BVXV) Stock Up Today?

    investorplace.com

    2022-03-24 13:15:37

    BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.

    https://images.financialmodelingprep.com/news/heres-why-biondvax-pharmaceuticals-shares-are-rising-20220324.jpg
    Here's Why Biondvax Pharmaceuticals Shares Are Rising

    benzinga.com

    2022-03-24 12:03:16

    Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid.